임신 중 salicylamide을 피해야 할까요? | VeriMom
ECHA REACH/registration data include Repr.2 / H361 notifications for salicylamide (CAS 65-45-2) submitted by registrants (not a harmonised Annex VI classification). This supports a 'suspected' reproductive hazard (h=2) but is not harmonised by the Commission. Mechanistic concern is class-based/theoretical (m=1) because salicylamide is a salicylate-related compound and salicylates are known to cross the placenta and be systemically available; direct mechanistic reproductive data for salicylamide are limited. Exposure from typical topical cosmetic use is expected to be low but measurable (evidence for dermal cosmetic exposure is limited), so e=1.
ECHA regulatory hazard statements
- •H361
What to use instead
Pregnancy-safe ingredients that serve a similar function:
FAQ
- salicylamide은 임신 중 안전한가요?
- ECHA REACH/registration data include Repr.2 / H361 notifications for salicylamide (CAS 65-45-2) submitted by registrants (not a harmonised Annex VI classification). This supports a 'suspected' reproductive hazard (h=2) but is not harmonised by the Commission. Mechanistic concern is class-based/theoretical (m=1) because salicylamide is a salicylate-related compound and salicylates are known to cross the placenta and be systemically available; direct mechanistic reproductive data for salicylamide are limited. Exposure from typical topical cosmetic use is expected to be low but measurable (evidence for dermal cosmetic exposure is limited), so e=1.
- salicylamide은 모유 수유 중 안전한가요?
- Registrants have notified H361 (Repr.2) for salicylamide; salicylate metabolites are known to be excreted in human milk (class-based evidence), so a suspected hazard to nursing infants is appropriate (h=2) but this is based on registrant classification and read-across from salicylates rather than a harmonised/regulatory SCCS/CIR conclusion for salicylamide specifically. Systemic exposure after topical use is likely low but non-zero (e=1).
- salicylamide은 아기 피부에 안전한가요?
- Hazard (h) and mechanism (m) are kept the same as adult because there is no infant-specific evidence to upscore hazard or mechanism. Exposure (e) is increased by +1 for infants (e=2) per your rules because infant skin has higher surface‑area‑to‑weight and an immature barrier and salicylamide is a small molecule with some dermal absorption potential; therefore infant dermal exposure is moderately greater than adult.
- VeriMom은 salicylamide을 어떻게 평가하나요?
- VeriMom은 EU CosIng, ECHA 분류, PubMed 연구를 기반으로 salicylamide을 27/100 (높은 위험)로 평가합니다.
- 임신 중 salicylamide 대체 안전 성분은?
- 유사한 기능을 가진 알려진 위험이 없는 대체 성분 목록을 확인하세요.
모든 성분표를 2초 만에 확인
VeriMom 무료 다운로드 — 어떤 제품이든 스캔해 임신 중 안전 점수를 즉시 확인하세요.
의료 면책 조항
이 정보는 교육 목적으로만 제공되며 의학적 조언을 구성하지 않습니다. 안전 점수는 공개적으로 이용 가능한 데이터를 기반으로 하며 모든 위험을 반영하지 않을 수 있습니다. 임신 중 또는 수유 중 제품을 사용하기 전에 항상 의료 전문가와 상담하십시오.